Papers/PMID:41261512
Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment.
Integrative cancer therapies2025The record
1 finding drawn from this paper, on 1 compound across 1 endpoint, 1 of them null.
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
coenzyme Q10 — no detected effect on total antioxidant capacity
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull resultreplicated ×2“There was no statistically significant change in TAC between the patients treated with doxorubicin + CoQ10 and doxorubicin + placebo.”
Quoted verbatim from Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment.. - Study
- crossover
- Participants
- 6
- Dose
- 300 mg/day, two 150 mg softgel capsules once daily with food
- Population
- Women aged 21 or older with stage I-III breast cancer receiving dose-dense doxorubicin plus cyclophosphamide, each acting as her own control across one cycle with coenzyme Q10 and one with placebo; secondary endpoint.
Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment.2025PMID:41261512